

63. Webster GF, Sugarman J, Levy-Hacham O, Toledano O. Microencapsulated benzoyl peroxide and tretinoin for the treatment of acne vulgaris: results from a phase 2 multicenter, double-blind, randomized, vehicle-controlled study. *Skinmed*. 2020;18(6):343-351.
64. Gollnick HP, Draelos Z, Glenn MJ, et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. *Br J Dermatol*. 2009;161:1180-1189.
65. Kawashima M, Hashimoto H, Alio Saenz AB, Ono M, Yamada M. Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study. *J Dermatol*. 2014;41(9):795-801.
66. Eichenfield LF, Alio Saenz AB. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. *J Drugs Dermatol*. 2011;10:1382-1396.
67. Smith EB, Padilla RS, McCabe JM, Becker LE. Benzoyl peroxide lotion (20 percent) in acne. *Cutis*. 1980;25:90-92.
68. Chalker DK, Shalita A, Smith JG, Swann RW. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. *J Am Acad Dermatol*. 1983;9:933-936.
69. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. *J Am Acad Dermatol*. 1997;37:590-595.
70. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. *Clin Exp Dermatol*. 1992;17:165-168.
71. Jarratt MT, Brundage T. Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study. *J Drugs Dermatol*. 2012;11:318-326.
72. Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. *Br J Dermatol*. 2011;165:177-183.
73. Baldwin HE, Green LJ, Kircik L, Guenin EP, Forest AL, Pillai R. Tazarotene 0.045% lotion for moderate-to-severe acne in male and female participants: a phase II post-hoc analysis. *J Clin Aesthet Dermatol*. 2021;14:E53-E60.
74. Lain E, Day D, Harper J, Guenin E. Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: impact of gender and Race on efficacy and safety. *J Drugs Dermatol*. 2019;18(11):1128-1138.
75. Green LJ, Del Rosso JQ, Tangheiti EA, Guenin E. Tazarotene 0.045% lotion for moderate-to-severe acne patients: pooled phase 3 analysis by age and sex. *J Drugs Dermatol*. 2021;20(6):608-615.
76. Stein Gold L, Pariser DM, Guenin E. Tretinoin 0.05% lotion for the once-daily treatment of moderate and severe acne vulgaris in females: effect of age on efficacy and tolerability. *J Drugs Dermatol*. 2019;18(12):1218-1225.
77. Paracha MM, Ullah I, Zahoor H, Kammal K. Efficacy and safety of short term use of 0.1% tazarotene gel in the treatment of mild to moderate acne vulgaris: a randomized-vehicle controlled trial. *J Postgrad Med Inst*. 2020;34(2):134-138.
78. Alirezai M, George SA, Coutts I, et al. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. *Eur J Dermatol*. 2007;17:45-51.
79. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. *Dermatology (Basel, Switzerland)*. 1999;199:242-247.
80. Tangheiti EA, Kircik LH, Green LJ, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. *J Drugs Dermatol*. 2019;18(6):542.
81. Chalker DK, Leshner JL, Smith JG, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. *J Am Acad Dermatol*. 1987;17:251-254.
82. Harper JC, Baldwin H, Stein Gold L, Guenin E. Efficacy and tolerability of a novel tretinoin 0.05% lotion for the once-daily treatment of moderate or severe acne vulgaris in adult females. *J Drugs Dermatol*. 2019;18(11):1147-1154.
83. Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. *J Drugs Dermatol*. 2007;6:981-987.
84. Eichenfield LF, Lain T, Frankel EH, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: second of two identically designed, large, multicenter, randomized, vehicle-controlled trials. *J Drugs Dermatol*. 2016;15(8):962-969.
85. Stein Gold LF, Jarratt MT, Bucko AD, et al. Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle-controlled trials. *J Drugs Dermatol*. 2016;15(5):553-561.
86. Alexis A, Del Rosso JQ, Desai SR, et al. BPX-01 minocycline topical gel shows promise for the treatment of moderate-to-severe inflammatory acne vulgaris. *J Clin Aesthet Dermatol*. 2018;11(11):25-35.
87. Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study. *J Am Acad Dermatol*. 2020;82(4):832-837.
88. Pochi PE, Bagatell FK, Ellis CN, et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. *Cutis*. 1988;41:132-136.
89. Dobson RL, Belknap BS. Topical erythromycin solution in acne: results of a multiclinic trial. *J Am Acad Dermatol*. 1980;3:478-482.
90. Bernstein JE, Shalita AR. Topically applied erythromycin in inflammatory acne vulgaris. *J Am Acad Dermatol*. 1980;2:318-321.
91. Leshner JL, Chalker DK, Smith JG, et al. An evaluation of a 2% erythromycin ointment in the topical therapy of acne vulgaris. *J Am Acad Dermatol*. 1985;12:526-531.
92. Becker LE, Bergstresser PR, Whiting DA, et al. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. *Arch Dermatol*. 1981;117:482-485.
93. Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. *JAMA Dermatology*. 2020;156(6):621-630.